Fibrolamellar hepatocellular carcinoma (FLC) is a rare subtype of primary liver cancer. Fibrolamellar hepatocellular carcinoma was first described Edmondson in 1956.[1][2] Fibrolamellar hepatocellular carcinoma is most commonly seen in children and young adults. The pathogenesis of fibrolamellar hepatocellular carcinoma is characterized by the lack of cirrhosis. Common causes of fibrolamellar hepatocellular carcinoma, include: active hepatic inflammation, hepatitis B or C viral infection, alcohol-related liver disease, nonalcoholic fatty liver disease, and dietary aflatoxin B1. The majority of patients with fibrolamellar hepatocellular carcinoma remain asymptomatic for years. Early clinical features include abdominal pain, weight loss, and malaise. If left untreated, the majority of patients with fibrolamellar hepatocellular carcinoma may progress to develop metastasis to abdominal lymph nodes, peritoneum, and lung. Common complications of fibrolamellar hepatocellular carcinoma include: hepatic ...
Headline: Bitcoin & Blockchain Searches Exceed Trump! Blockchain Stocks Are Next!. Metastatic Hepatocellular Carcinoma (HCC) market report covers research informatics related to Metastatic Hepatocellular Carcinoma (HCC) clinical trials, such as a listing of industry and sponsored clinical trials as well as new drug therapies.. Designed to be a resource both for patients interested in participating in Metastatic Hepatocellular Carcinoma (HCC) clinical trials and for research professionals.. The report, "Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016″ provides an overview of Metastatic Hepatocellular Carcinoma (HCC) clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Hepatocellular Carcinoma (HCC). Report includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), ...
Gehring, A.J., Ho, Z.Z., Tan, A.T., Bertoletti, A., Aung, M.O., Lim, S.G., Lee, K.H., Tan, K.C., Lim, S.G. (2009). Profile of Tumor Antigen-Specific CD8 T Cells in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma. Gastroenterology 137 (2) : 682-690. [email protected] Repository. https://doi.org/10.1053/j.gastro.2009.04. ...
On May 29, 2020, the FDA approved the immunotherapy atezolizumab (Tecentriq; Genentech), a PD-L1 inhibitor, in combination with bevacizumab (Avastin; Genentech), a vascular endothelial growth factor inhibitor, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received systemic therapy. This is the first immunotherapy regimen approved by the FDA for this type of HCC.
Fibrolamellar hepatocellular carcinoma (FHCC) is a rare form of hepatocellular carcinoma (HCC) that typically affects young adults and is characterized, under the microscope, by laminated fibrous layers interspersed between the tumour cells. Approximately 200 new cases are diagnosed worldwide each year. A recent study showed the presence of the DNAJB1-PRKACA chimeric transcript (resulting from a 400kb somatic deletion on chromosome 19) in 100% of the FHCCs examined (15/15) This gene fusion has been confirmed in a second study. The histopathology of FHCC is characterized by laminated fibrous layers, interspersed between the tumor cells. Cytologically, the tumor cells have a low nuclear to cytoplasmic ratio with abundant eosinophilic cytoplasm. Tumors are non-encapsulated, but well circumscribed, when compared to conventional HCC (which typically has an invasive border). Due to lack of symptoms, until the tumor is sizable, this form of cancer is often advanced when diagnosed. Symptoms include ...
Sigma-Aldrich offers abstracts and full-text articles by [Seung In Seo, Hyoung Su Kim, Won Jin Kim, Woon Geon Shin, Doo Jin Kim, Kyung Ho Kim, Myoung Kuk Jang, Jin Heon Lee, Joo Seop Kim, Hak Yang Kim, Dong Joon Kim, Myung Seok Lee, Choong Kee Park].
Hepatoma Research is an open access journal and focuses on all topics related to hepatoma. The following articles are especially welcome: pathogenesis, clinical examination and early diagnosis of hepatoma, complications of hepatoma, and their preventions and treatments, etc.
It has been estimated that 70% to 90% of patients with hepatocellular carcinomas have an established background of chronic liver disease or cirrhosis, the major causes of which are HBV or HCV infection (26, 27). More than 50% (340,000 cases) of all hepatocellular carcinomas worldwide are associated with HBV infection and near 30% (195,000 cases) are HCV infection-related (28, 29). Once cirrhosis is established, the annual risk of developing hepatocellular carcinoma is estimated to be as high as 3% to 4% (30). Screening for hepatocellular carcinoma using serum AFP or combined with ultrasonography in these high-risk populations is still the essential way for detection and diagnosis of hepatocellular carcinomas at an earlier stage, when curative therapies are likely to be more successful (31, 32).. On the basis of the specific screening requirements for hepatocellular carcinomas in the context of chronic liver disease and cirrhosis and the general criteria for an adequate screening test to detect ...
To the editor: We are writing in response to the letter (1) on fibrolamellar hepatocellular carcinoma, in which Ruffin points out that the cases of this tumor reported since 1941 have all originated in the United States. We report two cases of this tumor diagnosed in patients treated at our hospital.. A 25-year-old man was hospitalized for epigastric discomfort; anorexia was present for 5 months. Physical examination showed a liver edge 12 cm below the right costal margin. The erythrocyte sedimentation rate was 135 mm/h; alkaline phosphatase, 100 U/L (normal, ≤ 40 U/L); and gamma-glutamyltransferase, 89 IU/L (normal, ≤ 30 ...
Dynamic monitoring of serum alpha-fetoprotein and its correlation with early hepatocellular carcinoma in patients with chronic hepatitis B, Qing-Feng Chen, Xiao-Min Luo, Mei-Ping Z
AIM: To investigate the antitumor effects of cytosine deaminase (CD) gene in combination with prodrug flucytosine (Flu, 5-fluorocytosine) on human hepatocellular carcinoma. METHODS: CD gene was transduced into human hepatocellular carcinoma cell line
TY - JOUR. T1 - Altered findings of hepatic arteriography after radiofrequency ablation of hepatocellular carcinoma. T2 - Comparison of pre-ablation and post-ablation angiograms. AU - Kim, Byung Moon. AU - Cho, Jae Hyun. AU - Won, Je Hwan. AU - Lee, Do Yun. AU - Lee, Jong Tae. AU - Kim, Hyun Cheol. AU - Park, Sung Il. PY - 2007/6/1. Y1 - 2007/6/1. N2 - Objective: To evaluate the altered findings of hepatic arteriography after radiofrequency (RF) ablation of hepatocellular carcinoma which can potentially influence subsequent transcatheter arterial chemoembolization. Materials and methods: Hepatic arteriograms of 26 index hepatocellular carcinomas in 24 patients treated only by RF ablation (M:F = 22:2, mean age 55 years), in which hepatic arteriography was performed before and after RF ablation, were retrospectively compared for the altered findings. Results: The altered findings of hepatic arteriography after RF ablation of the hepatocellular carcinoma were arterio-portal shunt (n = 3), ...
TY - JOUR. T1 - Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AU - Kim, Seong Hyun. AU - Choi, Dongil. AU - Kim, Seung Hoon. AU - Lim, Jae Hoon. AU - Lee, Won Jae. AU - Kim, Min Ju. AU - Lim, Hyo K.. AU - Lee, Soon Jin. PY - 2005/1/1. Y1 - 2005/1/1. N2 - OBJECTIVE. We compared ferucarbotran-enhanced MRI with triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. SUBJECTS AND METHODS. Seventy-three consecutive patients with 121 hepatocellular carcinomas underwent ferucarbotran-enhanced MRI, including a dynamic study, and triple-phase MDCT before hepatic resection. The diagnosis of hepatocellular carcinoma was confirmed in all patients by means of pathologic examination after surgical resection. Three experienced radiologists independently reviewed the MR and CT images on a segment-by-segment basis. The accuracy of these techniques for the detection of hepatocellular carcinoma was assessed by conducting a ...
Many chemotherapeutic agents have been successfully used to treat hepatocellular carcinoma (HCC);however, the development of chemoresistance in liver cancer cells usually results in a relapse and worseningof prognosis. It has been demonstrated that DNA methylation and histone modification play crucial roles inchemotherapy resistance. Currently, extensive research has shown that there is another potential mechanismof gene expression control, which is mediated through the function of short noncoding RNAs, especially formicroRNAs (miRNAs), but little is known about their roles in cancer cell drug resistance. In present study, bytaking advantage of miRNA effects on the resistance of human hepatocellular carcinoma cells line to cisplatin, ithas been demonstrated that miR-340 were significantly downregulated whereas Nrf2 was upregulated in HepG2/CDDP (cisplatin) cells, compared with parental HepG2 cells. Bioinformatics analysis and luciferase assays ofNrf2-3-untranslated region-based reporter constructor
TY - JOUR. T1 - Lipocalin-2 Induces Apoptosis in Human Hepatocellular Carcinoma Cells Through Activation of Mitochondria Pathways. AU - Chien, Ming Hsien. AU - Ying, Tsung Ho. AU - Yang, Shun Fa. AU - Yu, Ji Kuen. AU - Hsu, Chih Wei. AU - Hsieh, Shu Ching. AU - Hsieh, Yi Hsien. PY - 2012. Y1 - 2012. N2 - Lipocalin 2 (LCN2) is a secreted, iron-binding glycoprotein that is abnormally expressed in some malignant human cancers. However, the roles of LCN2 in hepatocellular carcinoma (HCC) cells are unknown. In this study, we suggested the LCN2 and LCN2R were weak detected in the HCC cell lines, LCN2 and LCN2R were found to be down-regulated in tumor tissues in 16 HCC patients. MTT, DAPI, TUNEL, and flow cytometry analyses revealed that LCN2 overexpression dramatically inhibited cell viability, induced apoptosis features of cell-cycle arrest in sub-G1 phase, in DNA fragmentation, and in condensation of chromatin in Huh-7 and SK-Hep-1 cells. Western blots were used to detect the activation of caspase, ...
Hepatocellular carcinoma (HCC) is a serious consequence of persistent hepatitis C virus (HCV) infection and represents one of the most aggressive neoplasms globally. The implication of microRNA-301...
HCC is the third most common cancer worldwide, causing about 700,000 deaths annually.2 It is associated with cirrhosis, hepatitis B and C virus, primary biliary and sclerosing cholangitis, aflatoxins, and autoimmune hepatitis.2,3 Extrahepatic metastatic HCC, as observed in this case, occur in 30-50% of HCC patients; the most common sites are lungs, bones, adrenal glands, and lymph nodes.4 Rare and unusual metastatic sites have been described in the literature, including the chest wall presenting as a breast mass and metastasis to the nasal septum.5,6 Indeed, extrahepatic metastases to the humeral shoulder, chest wall, and bony lesions are exceedingly rare, as only a handful of cases have been reported.3,7 Traditionally, a few systems have been widely employed for HCC staging (e.g. Okuda, tumor/node/metastasis), however, newer classification systems that take into account prognostication and treatment regimens are increasingly being utilized.8 The Cancer of the Liver Italian Program (CLIP) and ...
TY - JOUR. T1 - Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. AU - Yoon, Eileen L.. AU - Yeon, Jong Eun. AU - Lee, Hyun Jung. AU - Suh, Sang Jun. AU - Lee, Sun Jae. AU - Kang, Seong Hee. AU - Kang, Keunhee. AU - Yoo, Yang Jae. AU - Kim, Ji Hoon. AU - Yim, Hyung Joon. AU - Byun, Kwan Soo. PY - 2014/3/1. Y1 - 2014/3/1. N2 - GOALS:: The goal of the study was to compare the efficacy and safety of sorafenib with those of systemic cytotoxic chemotherapy. BACKGROUND:: Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo. However, whether sorafenib controls advanced-stage HCC better than systemic cytotoxic chemotherapy has not been elucidated. STUDY:: We retrospectively reviewed the medical records of 220 patients with measurable advanced HCC who had not received systemic treatment previously between January 2007 and April 2012. Among these ...
TY - JOUR. T1 - Recurrent hepatocellular carcinoma after liver transplant. T2 - Identifying the high-risk patient. AU - Nissen, Nicholas N.. AU - Menon, Vijay. AU - Bresee, Catherine. AU - Tran, Tram T.. AU - Annamalai, Alagappan. AU - Poordad, Fred. AU - Fair, Jeffrey H.. AU - Klein, Andrew S.. AU - Boland, Brendan. AU - Colquhoun, Steven D. PY - 2011/1/1. Y1 - 2011/1/1. N2 - Background: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is rarely curable. However, in view of the advent of new treatments, it is critical that patients at high risk for recurrence are identified. Methods: Patients undergoing LT for HCC at a single centre between 2002 and 2010 were reviewed and data on clinical parameters and explant pathology were analysed to determine factors associated with HCC recurrence. All necrotic and viable tumour nodules were included in explant staging. All patients underwent LT according to the United Network for Organ Sharing (UNOS) Model for End-stage Liver ...
Gentaur molecular products has all kinds of products like :search , US Biomax \ Hepatocellular carcinoma tissue array, 63 cases_63 cores, replaced by LV809 \ BS03014 for more molecular products just contact us
Sorafenib improves overall survival and progression free survival in advanced hepatocellular carcinoma. Wide interindividual pharmacokinetic variability was observed. Data from early phase trials in solid tumours showed trough sorafenib levels were associated with incidence of skin rash and hypertension. Rash, hypertension and higher trough levels were moderately predictive of progression free survival.The trough level of sorafenib may be predictive of survival and response in patients treated with sorafenib for advanced hepatocellular carcinoma ...
Background To compare the RapidArc plan for primary hepatocellular carcinoma (HCC) with 3-D conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) plans using dosimetric analysis.
We describe a case of acute liver failure in a patient with advanced hepatocellular carcinoma related to nonalcoholic steatohepatitis during sorafenib treatment. A 74-year-old man with diabetes mellitus and hypertension was diagnosed with hepatocellular carcinoma associated with fatty liver. Three weeks after sorafenib therapy, at Eastern Cooperative Oncology Group performance status 3, he developed jaundice, general weakness, flapping tremor, nausea, and anorexia. Sorafenib was stopped: laboratory tests showed a relevant elevation of transaminases suggesting diagnosis of acute hepatitis. During hospital admission, the patient died of liver failure. Sorafenib is the first successful target therapy effective for advanced hepatocellular carcinoma. The most common adverse events are fatigue, hand-foot skin reaction, skin rash/desquamation, diarrhea, and hypertension, whereas liver dysfunction is uncommon. To our knowledge, this is the first patient reported in the literature with hepatocellular ...
TY - JOUR. T1 - Surgical Resection vs. Ablative Therapies Through a Laparoscopic Approach for Hepatocellular Carcinoma: a Comparative Study. AU - Santambrogio, Roberto. AU - Santambrogio, Roberto. AU - Barabino, Matteo. AU - Bruno, Savino. AU - Mariani, Nicolò. AU - Maroni, Nirvana. AU - Bertolini, Emanuela. AU - Franceschelli, Giuseppe. AU - Opocher, Enrico. PY - 2017/12/12. Y1 - 2017/12/12. N2 - © 2017 The Society for Surgery of the Alimentary Tract Background: When compatible with the liver functional reserve, laparoscopic hepatic resection remains the treatment of choice for hepatocellular carcinoma while laparoscopic ablation therapies appear as a promising less invasive alternative. The aim of the study is to compare two homogeneous groups of patients submitted to either hepatic resection or thermoablation for the treatment of single hepatocellular carcinoma (≤ 3 cm). Methods: We enrolled 264 cirrhotic patients out of 905 cases consecutively evaluated for hepatocellular carcinoma. We ...
TY - JOUR. T1 - An overview of loco-regional treatments in patients and mouse models for hepatocellular carcinoma. AU - Bimonte, Sabrina. AU - Barbieri, Antonio. AU - Palaia, Raffaele. AU - Leongito, Maddalena. AU - Albino, Vittorio. AU - Piccirillo, Mauro. AU - Arra, Claudio. AU - Izzo, Francesco. PY - 2015/3/9. Y1 - 2015/3/9. N2 - Hepatocellular carcinoma is a highly aggressive malignancy and is the third leading cause of cancer-related deaths worldwide. Although surgery is currently considered the most effective curative treatment for this type of cancer, it is note that most of patients have a poor prognosis due to chemioresistence and tumor recurrence. Loco-regional therapies, including radiofrequency ablation, surgical resection and transcatheter arterial chemoembolization play a major role in the clinical management of hepatocellular carcinoma. In order to improve the treatment outcome of patients diagnosed with this disease, several in vivo studies by using different techniques on cancer ...
1. Patel M, Shariff M I, Ladep N G. et al. Hepatocellular carcinoma: diagnostics and screening. J Eval Clin Pract. 2012;18:335-42 2. Padhya K T, Marrero J A, Singal A G. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013;29:285-92 3. Schoenleber S J, Kurtz D M, Talwalkar J A, Roberts L R, Gores G J. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer. 2009;100:1385-92 4. Miura S, Mitsuhashi N, Shimizu H. et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer. 2012;12:56 5. Lassalle P, Molet S, Janin A. et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271:20458-64 6. Bechard D, Meignin V, Scherpereel A. et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal ...
Background and aims. Information on the impact of therapeutic strategies of hepatocellular carcinoma is still incomplete due to the lack of surveys involving primary-care centres. Patients and methods. The Gruppo Epatologico Lombardo (GEL) carried out a study on 361 incident hepatocellular carcinoma observed from January to December 1998 in 22 hospitals in Lombardy. The clinical, pathological and therapeutic data were collected from all patients; 5-year survival and factors related to outcome were analysed. Results. Two hundred and ninety-seven patients were male (M[F: 4.6/1, mean age 66); 61% were HCV-pos, 15% HBV-pos, 17% alcoholic. Cirrhosis was present in 333 (92%) and was classified as Child-A in 197 (59%), Child-B in 85 (26%) and Child-C in 51 (15%) cases. Hepatocellular carcinoma was multifocal/diffuse (more than three nodules) in 91 (25%), less than three nodules in 86 (24%) and monofocal in 184 (51 %) (,= 3 cm in 146). As to the therapy: 145 hepatocellular carcinomas (40%) were ...
RESULTS: Seven patients (median age 21 years, range 19 - 42, 5 men, 2 women) underwent surgery for FLC. No patient had underlying liver disease or an elevated alpha feto-protein (AFP) at either initial presentation or recurrence. Six patients had a solitary tumour at diagnosis (mean largest diameter = 12cm), and underwent left hepatectomy (N=2), right hepatectomy (N=1), extended right hepatectomy (N=1), and segmentectomies (N=2). Three patients underwent a portal lymphadenectomy for regional lymphatic tumour involvement. One patient with advanced extrahepatic portal nodal metastasis was unresectable. No peri-operative deaths occurred. Recurrence occurred post resection in all 6 patients. Median overall survival was 60 months, and overall 5-year survival was 4 out of 7 (57%). Post-resection survival (N=6) was 61 months, with a 5-year survival rate of 4 out of 6 (67%). The patient with unresectable disease survived 38 months after tumour embolisation with Lipiodol ...
Hepatocellular carcinoma is considered to be the fifth most common cancer worldwide. Resection and liver transplantation have a high survival in the correct clinical scenarios; however, locoregional therapy has many advantages over tumor resection like preservation of hepatic parenchyma and overall less morbidity and mortality. Our aim was to present the role of dynamic subtraction MRI technique in the assessment of treatment response of hepatocellular carcinoma to transarterial chemoembolization. The study consisted of 43 patients with 55 hepatocellular carcinoma lesions who underwent transarterial chemoembolization procedure and followed up by dynamic MRI of the liver with post processing to obtain subtraction images 1-1.5 months after the procedure. If no signs of disease activity, another follow up study was preformed 2-4 months later. Five patients were excluded due to misregistration artifact at the subtraction images. The final cohort is 38 patients having 50 lesions. Precontrast T1, T2, dynamic
TY - JOUR. T1 - Increased Regulatory T Cells Correlate With CD8 T-Cell Impairment and Poor Survival in Hepatocellular Carcinoma Patients. AU - Fu, Junliang. AU - Xu, Dongping. AU - Liu, Zhenwen. AU - Shi, Ming. AU - Zhao, Ping. AU - Fu, Baoyun. AU - Zhang, Zheng. AU - Yang, Huiyin. AU - Zhang, Hui. AU - Zhou, Chunbao. AU - Yao, Jinxia. AU - Jin, Lei. AU - Wang, Huifen. AU - Yang, Yongping. AU - Fu, Yang Xing. AU - Wang, Fu Sheng. PY - 2007/6. Y1 - 2007/6. N2 - Background & Aims: Recent studies have suggested that CD4+CD25+ regulatory T cells (Treg) are increased and linked to compromised immune responses in patients with hepatocellular carcinoma (HCC). This study attempted to further characterize CD4+CD25+ forkhead/winged helix transcription factor (FoxP3)+ Treg in blood, tumor, and nontumor liver tissues of HCC patients, and to understand how the Treg affects immune responses and contributes to disease progression. Methods: A total of 123 HCC patients with chronic hepatitis B virus (HBV) ...
Fibrolamellar hepatocellular carcinoma (FL-HCC) is generally a fairly rare event in routine pathology practice. This variant of hepatocellular carcinoma (HCC) is peculiarly intriguing and,in addition, poorly understood. Young people or children are often the target individuals with this type of cancer. Previously, I highlighted some pathology aspects of FL-HCC, but in this review, the distinctive clinico-pathologic features of FL-HCC and the diagnostic pathologic criteria of FL-HCC are fractionally reviewed and expanded upon. Further, molecular genetics update data with reference to this specific tumor are particularly highlighted as a primer for general pathologists and pediatric histopathologists. FL-HCC may present with metastases, and regional lymph nodes may be sites of metastatic spread. However, peritoneal and pulmonary metastatic foci have also been reported. To the best of our knowledge, FL-HCC was initially considered having an indolent course, but survival outcomes have recently been updated
CD80 transfected human hepatocellular carcinoma cells activate cytotoxic T lymphocytes to target HCC cells with shared tumor antigens
We read with interest the article by Bruix et al1 in which Sorafenib was regarded as the standard treatment for hepatocellular carcinoma (HCC) patients with portal vein tumour thrombosis (PVTT). However, Sorafenib can only confer 2-3 months of overall survival (OS) benefit2 ,3 and is inapplicable to many patients due to extensive side effects and high price. Zhong et al4 proposed that liver resection might provide survival benefit to patients with HCC-PVTT with adequate liver function. However, this proposal was based on literature survey, lacked definite patient inclusion criteria and failed to provide information on patients baseline characteristics. Therefore, explorations of alternative therapeutics for patients with HCC-PVTT are still needed.. Although not recommended by mainstream guidelines5 ,6 for patients with HCC-PVTT, transarterial chemoembolisation (TACE) has long been practiced in the clinic in selected patients with HCC-PVTT.7 ,8 Gamma knife surgery (GKS) has shown favourable ...
Liver Cancer (hepatocellular carcinoma). Medical Term: None Specified. Description:. A malignant tumor arising from liver cells. Although much less common than metastatic liver cancer in most areas of the world, hepatocellular carcinoma is the most common internal malignancy and an important cause of death in certain areas of Africa and Southeast Asia. This is mainly because of the high incidence of Hepatitis B in these areas.. In North America, hepatocellular carcinoma is mainly associated with cirrhosis of the liver.. Causes: Unknown. As noted above, there is a high association with Hepatitis B and C, and cirrhosis of liver.. Prevention: Hepatitis B vaccination and prevention education for high-risk individuals. Minimize alcohol use.. Signs & Symptoms. ...
1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576 2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533-543 3. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology. 2011;53:1020-1022 4. Wilhelm SM, Carter C, Tang L. et al. BAY 43-9006 exhibits broad spectrum oral anticancer activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109 5. Chang YS, Adnane J, Trail PA. et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vasculization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561-574 6. Llovet JM, Ricci S, Mazzaferro V. et al. for the SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390 7. Cheng AL, Kang YK, Chen Z. et al. Efficacy and safety of ...
MicroRNAs (miRNAs) belong to the subgroup of small noncoding RNAs, which typically serve as important gene regulators to participate in different biological events, such as tumor cell growth and apoptosis. Recent studies indicated microRNA-4651 (miR-4651) was involved in hepatocellular carcinoma (HCC) progression. The certain role of miRNA-4651 during the progression of HCC, however, remains unclear. Herein, we investigated the mRNA expression level of miR-4651 in HCC tissues and HCC cell lines and found miR-4651 was noticeably downregulated compared with the normal liver tissues and QSG-7701 cell line, respectively. Then, miR-4561 overexpression obviously repressed the proliferation and promoted apoptosis in two HCC cell lines. Interestingly, we further identified that miR-4561 could directly interact with FOXP4 in HCC cells by using bio-informatic method and report assay. Moreover, forced expression of FOXP4 showed an opposite effect compared with miR-4561 in HCC cell lines. Hence, our ...
This trial assessed the efficacy and safety of sorafenib in advanced hepatocellular carcinoma patients in SEER-Medicare Database. The study determined the
BACKGROUND: Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy (SIRT) with yttrium-90 ((90)Y) resin microspheres in patients with hepatocellular carcinoma. METHODS: SARAH was a multicentre, open-label, randomised, controlled, investigator-initiated, phase 3 trial done at 25 centres specialising in liver diseases in France. Patients were eligible if they were aged at least 18 years with a life expectancy greater than 3 months, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, Child-Pugh liver function class A or B score of 7 or lower, and locally advanced hepatocellular carcinoma (Barcelona Clinic Liver Cancer [BCLC] stage C), or new hepatocellular carcinoma not eligible for surgical resection, liver transplantation, or thermal ablation after a previously cured hepatocellular carcinoma (cured by surgery or thermoablative ...
TY - JOUR. T1 - Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. AU - Chang, Te Sheng. AU - Wu, Yu Chih. AU - Tung, Shui Yi. AU - Wei, Kuo Liang. AU - Hsieh, Yung Yu. AU - Huang, Hao Chun. AU - Chen, Wei Ming. AU - Shen, Chien Heng. AU - Lu, Chang Hsien. AU - Wu, Cheng Shyong. AU - Tsai, Ying Huang. AU - Huang, Yen Hua. PY - 2015/6/10. Y1 - 2015/6/10. N2 - Liver cirrhosis is a major risk factor for hepatocellular carcinoma (HCC), and all liver study societies recommend HCC surveillance in patients with cirrhosis. However, no ideal modality for HCC surveillance has been determined. The aim of this study is to assess the effectiveness of α-fetoprotein (AFP) measurement in HCC surveillance.METHODS:In this retrospective analysis, all patients with cirrhosis, who received HCC surveillance through ultrasound (US) and AFP measurement between January 2002 and July 2010, were followed up until June 2013. The performance effectiveness of ...
Conference Paper: Pathway analysis of genome-wide association data on hepatocellular carcinoma in southern Chinese patients with chronic hepatitis B virus ...
Sigma-Aldrich offers abstracts and full-text articles by [Gek San Tan, Kiat Hon Lim, Hwee Tong Tan, May Lee Khoo, Sze Huey Tan, Han Chong Toh, Maxey Ching Ming Chung].
Objective: To investigate the prognostic relationship between the expression levels of periostin (POSTN) in hepatocellular carcinoma (HCC) tissues as well as its effect in invasion and metastasis. Methods: The expression levels of POSTN in liver cancer tissues were detected with real-time quantitative PCR (QPCR) and immunohistochemistry (IHC). Kaplan-Meier method and Log-rank test were used to analyze the relationship between POSTN expression level and postoperative prognosis in patients with liver cancer. The expression of POSTN in hepatocellular carcinoma cells with different metastasis characteristics were detected in vitro and the overexpression of POSTN in low metastatic hepatocellular carcinoma cells was mediated through plasmid transfection techniques. The effects of POSTN on invasion and metastasis of hepatocellular carcinoma cells were determined by transwell migration and matrigel invasion assay. The comparative expression level of POSTN was analyzed by t-test. Results: The expression ...
10.1055/b-0035-129536 6 Hepatocellular Carcinoma: RadioembolizationAvnesh S. Thakor, Arash Eftekhari, Edward Wolfgang Lee, Darren Klass, and David Liu 6.1 Introduction 6.1.1 Hepatocellular Carcinoma Overview Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the third leading cause of cancer mortality worldwide. Although HCC occurs more commonly in regions with a higher incidence…
MODULATOR IMPACTS OF PROPOLIS EXTRACT AGAINST DOXORUBICIN MEDIATED CARCINOGENESIS ON HEPATOCELLULAR CARCINOMA AND Drosophila SOMATIC CELLS
Hepatocellular carcinoma (HCC) is a common cause of cancer mortality in Asia. Most patients present with intermediate or advanced disease. Percutaneous ethanol injection, radiofrequency ablation, and transcatheter arterial chemoembolization (TACE) are not considered as a curative treatment and have achieved very limited success in eradicating large HCC. With the development of new radiotherapy (RT) technique, RT can be more safely given to patients with larger tumor burden. Thus, TACE combined with RT has been suggested for treating large HCC. Based on the results of these studies, RT could achieve a tumor response rate of 50 % to 70 %. However, it has not been definitively shown to prolong the overall or disease-free survival due to lack of a phase III clinical trial. In contrast, a retrospective clinical investigation with molecular study suggests that sublethal dose of RT promoted HCC growth outside RT field.. Two phase III trials were shown to be efficacious and well-tolerated in patients ...
We read with interest the article by Wang et al1 on zinc-finger protein 545 (ZNF545) acting as a tumour suppressor gene (TSG) in gastric cancer by inhibiting rRNA transcription and its methylation as a prognostic factor for early stages of gastric cancer. Inactivation of TSGs through promoter hypermethylation also plays an important role in progression of hepatocellular carcinoma (HCC).2-4 We wish to report the results of the expression profile and epigenetic regulation of ZNF545 in HCC, and its methylation role on early-stage HCC progression after thermal ablation.. Our results showed reduced or loss of ZNF545 expression was found in seven human hepatic cancer cell lines, including SMMC7721, PRF/PCL-5, SK-hep1, HepG2, BEL7402, LAM3 and SNU449, by semiquantitative reverse transcription PCR. Expression of ZNF545 was detected in another cell of HBXF344. The methylation status of the ZNF545 promoter was examined by methylation-specific PCR (MSP). Complete methylation of the ...
Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein Marine Gilabert,1,2 Jean-Luc Raoul3 1Department of Medical Oncology, Paoli-Calmettes Institute, 13232 Marseille Cedex 9, France; 2Centre de Recherche en Cancérologie de Marseille, Stress Cell Unit, Institut National de la Sante et de la Recherche Medicale 1068, Aix-Marseille University, Cedex 8, Marseille, France; 3Department of Medical Oncology, Institut de Cancérologie de l’Ouest René Gauducheau, 44805 Nantes, France Abstract: Hepatocellular carcinoma (HCC) represents ~90% of primary liver cancers and constitutes a major global health problem. Since a decade ago, the management of advanced disease that cannot be locally treated has mainly been based on multi-targeted antiangiogenic therapies. Some have demonstrated improvement in overall survival over best supportive care in first- and second-line treatment. This study focused on the efficacy of antiangiogenics in
TY - JOUR. T1 - Roles of ethnicity in survival of hepatocellular carcinoma patients in Malaysia. AU - Mohammed Nawi, Azmawati. AU - Krisnan, R.. PY - 2012. Y1 - 2012. N2 - The incidence of hepatocellular carcinoma (HCC) in Malaysia for the year 2001 was 2.8 per 100,000 people. The mortality rate is increasing. A retrospective cohort study measuring the survival of HCC patients who received treatment in Selayang Hospital was conducted from 1 January 2003 to 31 December 2006. The main objectives of the study were to measure the survival of the patients and to understand the influencing factors, especially ethnicity. The subjects were newly diagnosed cases of HCC by CT scan and histopathological assessment who underwent futher investigations and treatments in Hospital Selayang (inception cohort). The survival time was measured from the date of diagnosis until the subjects died, or failed to follow-up at the end of the study period (31 December 2007). A total of 299 patients were selected with 95 ...
Cell culture. Human hepatocellular carcinoma cell line (Hep3B), human colorectal carcinoma cell line (SW620), and human normal lung fibroblast cell lines (NHLF and MRC5) were obtained from the American Type Culture Collection. Human hepatocellular carcinoma cell lines (BEL7404 and SMMC7721) and human normal liver cell lines (QSG7701 and L-02) were purchased from the Shanghai Cell Collection. HEK293 was obtained from Microbix Biosystems, Inc. Cells were maintained in humidified 37°C atmosphere containing 5% CO2 and cultured in DMEM (Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies), 4 mmol/L glutamine, 50 units/mL penicillin, and 50 μg/mL streptomycin.. Virus construction and production. The constructs including pCN205-EGFP and pCN205-IL-24 were generated according to the standard molecular cloning protocol. The homologous recombination between pCN205-EGFP and pCN205-IL-24 plasmids and pCN103 plasmid carrying oncolytic adenoviral backbone was done ...
Systemic chemotherapy is one of the most important treatment modalities for advanced hepatocellular carcinoma (HCC). Before the introduction of sorafenib, cytotoxic agents, hormonal therapies, or many combinations of these were the mainly used modalities for systemic chemotherapy of advanced HCC. However, such regimens were of only limited value in clinical practice, because some randomized controlled studies comparing promising regimens with no treatment or doxorubicin alone failed to show any overall survival advantage. In two pivotal phase III placebo-controlled studies, the SHARP trial and the Asia-Pacific trial, sorafenib was demonstrated to significantly delay the time to progression and the overall survival time in patients with advanced HCC. Therefore, sorafenib therapy has come to be acknowledged as a standard therapy for advanced HCC worldwide. After the introduction of sorafenib, a number of phase III trials of various molecular-targeted agents vs. sorafenib as first-line chemotherapy and of